Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost

Jakobsen, Anders; Mortensen, John Pløen; Bisgaard, Christer Z.; Lindebjerg, Jan; Hansen, Júlia; Rafaelsen, Søren Rafael

doi:10.1016/j.ijrobp.2005.07.969

Cited by 55 publications

(40 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a Danish phase II study the total dose was increased to 65 Gy to the tumour bed with endorectal brachytherapy of 5 Gy/1 fraction in large T3 rectal cancers resulting in promising 27% pCR [19] but phase III trials are needed to define the possible role of brachytherapy as treatment option.…”

Section: Discussionmentioning

confidence: 99%

Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC)

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC)

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…The test cohort included 65 patients who were treated according to two previously published studies (22,23) with long-course CRT between 2002 and 2005, comprising conventional radiotherapy of 60 Gy/30 fractions and supplemented by a brachytherapy boost of 5 Gy. Concomitant chemotherapy consisting of 300 mg/m 2 UFT (uracil-tegafur; molar ratio 4:1) and 22.5 mg isovorin was administered to patients on treatment days.…”

Section: Methodsmentioning

confidence: 99%

“…Concomitant chemotherapy was administered as previously described (24) Patient consent was obtained prior to inclusion in the studies (22)(23)(24) which were approved by the local ethics committee of The Regional Scientific Ethical Committee for Southern Denmark.…”

Section: Methodsmentioning

confidence: 99%

Single nucleotide polymorphisms in the HIF-1α gene and chemoradiotherapy of locally advanced rectal cancer

et al. 2012

Self Cite

View full text Add to dashboard Cite

“…There is evidence that increasing the dose of radiation improves the local control, and brachytherapy can be used to achieve this. [117][118][119] For radical treatments, a flexible multichannel applicator can be used with either simple 2D techniques using digital X-ray fluoroscopic imaging for planning or full 3D CT/MRI. The simple 2D technique is based on using the standard applicator geometry and prescribing to a distance of typically 10 mm from the applicator surface.…”

Section: 103mentioning

confidence: 99%

Recent developments and best practice in brachytherapy treatment planning

Lee

2014

BJR

View full text Add to dashboard Cite

Brachytherapy has evolved over many decades, but more recently, there have been significant changes in the way that brachytherapy is used for different treatment sites. This has been due to the development of new, technologically advanced computer planning systems and treatment delivery techniques. Modern, three-dimensional (3D) imaging modalities have been incorporated into treatment planning methods, allowing full 3D dose distributions to be computed. Treatment techniques involving online planning have emerged, allowing dose distributions to be calculated and updated in real time based on the actual clinical situation. In the case of early stage breast cancer treatment, for example, electronic brachytherapy treatment techniques are being used in which the radiation dose is delivered during the same procedure as the surgery. There have also been significant advances in treatment applicator design, which allow the use of modern 3D imaging techniques for planning, and manufacturers have begun to implement new dose calculation algorithms that will correct for applicator shielding and tissue inhomogeneities. This article aims to review the recent developments and best practice in brachytherapy techniques and treatments. It will look at how imaging developments have been incorporated into current brachytherapy treatment and how these developments have played an integral role in the modern brachytherapy era. The planning requirements for different treatments sites are reviewed as well as the future developments of brachytherapy in radiobiology and treatment planning dose calculation. CHANGES AND DEVELOPMENTS IN TREATMENT PLANNING TECHNIQUESWithin the past few decades, there have been some major changes to the way brachytherapy treatments are both planned and delivered, and the introduction of modern, three dimensional (3D) imaging techniques have contributed significantly. In the 1930s, before the advent of planning computers, treatment planning was carried out by simply following a set of rules according to a dosimetry system such as the Manchester system. [1][2][3] This system was originally developed for use with radium sources and provided information, in tabular form, for the dose specification and distribution of sources and was used for many years. An increase in radiation safety awareness in the 1970s and 1980s led to a decline in the use of radium in favour of the relatively newer and safer radioisotopes such as caesium-137 and iridium-192. Over the same period, technological advances in afterloading techniques and the wider implementation of computerized planning using planar radiographic imaging were being implemented in an attempt to verify the applicator or catheter positions and calculate patient-specific dose. Alongside these advances, the need to compare patients' treatments with those from other treatment centres was being recognized as an important scientific standardization of treatment. The International Commission on Radiation Units and Measurements (ICRU) reports 38 and 58, 4,5 details t...

show abstract

Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost

Cited by 55 publications

References 17 publications

Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC)

Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC)

Single nucleotide polymorphisms in the HIF-1α gene and chemoradiotherapy of locally advanced rectal cancer

Recent developments and best practice in brachytherapy treatment planning

Contact Info

Product

Resources

About